Several strategies are being pursued to increase the quality and quantity of influenza vaccines that are used on an annual basis including increasing the immunogenicity of currently licensed inactivated vaccines, delivery of inactive vaccines directly to the nasal mucosa, the use of cell lines for virus production and the use of live, attenuated vaccines. In addition, modern molecular biological techniques are being used to create and evaluate new vaccine approaches. This report will briefly review these different strategies and outline some of the potential advantages and challenges associated with them.